Similar articles

• Aberrant methylation of DNA-damage-inducible transcript 3 promoter is a common event in patients with myelodysplastic syndrome.

  Lin J, Wang YL, Qian J, Yao DM, Zhu ZH, Qian Z, Xu WR. Lin J, et al. Leuk Res. 2010 Aug;34(8):991-4. doi: 10.1016/j.leukres.2010.01.003. Epub 2010 Jan 29. Leuk Res. 2010. PMID: 20116099
• Hypomethylation of PRAME promoter is associated with poor prognosis in myelodysplastic syndrome.

  Qian J, Zhu ZH, Lin J, Ming Yao DM, Li Y, Yang J, Wang CZ. Qian J, et al. Br J Haematol. 2011 Jul;154(1):153-5. doi: 10.1111/j.1365-2141.2011.08585.x. Epub 2011 Apr 22. Br J Haematol. 2011. PMID: 21517806 No abstract available.
• Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients.

  Aggerholm A, Holm MS, Guldberg P, Olesen LH, Hokland P. Aggerholm A, et al. Eur J Haematol. 2006 Jan;76(1):23-32. doi: 10.1111/j.1600-0609.2005.00559.x. Eur J Haematol. 2006. PMID: 16343268
• Myelodysplastic syndromes: natural history and features of prognostic importance.

  Mufti GJ, Galton DA. Mufti GJ, et al. Clin Haematol. 1986 Nov;15(4):953-71. Clin Haematol. 1986. PMID: 3552350 Review. No abstract available.
• [Prognostic aspects of myelodysplastic syndromes].

  Ohyashiki K. Ohyashiki K. Nihon Rinsho. 2007 Jan 28;65 Suppl 1:671-5. Nihon Rinsho. 2007. PMID: 17474477 Review. Japanese. No abstract available.